Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model

Richard Mutell, Jaime L Rubin, T Christopher Bond, Tracy Mayne DaVita Clinical Research, Minneapolis, MN, USA Background: Ferric citrate (FC) is a phosphate binder in development for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD). In clinical trials, FC improved p...

Full description

Bibliographic Details
Main Authors: Mutell R, Rubin JL, Bond TC, Mayne T
Format: Article
Language:English
Published: Dove Medical Press 2013-04-01
Series:International Journal of Nephrology and Renovascular Disease
Online Access:http://www.dovepress.com/reduced-use-of-erythropoiesis-stimulating-agents-and-intravenous-iron--a12911